What is the appropriate management for a patient with high‑grade stenosis of the left carotid bulb?

Management of High-Grade Left Carotid Bulb Stenosis

The appropriate management depends critically on whether the stenosis is symptomatic or asymptomatic, with symptomatic patients requiring urgent carotid endarterectomy (CEA) within 14 days if stenosis is ≥70%, while asymptomatic patients should receive optimal medical therapy (OMT) as the primary treatment, with revascularization reserved only for highly selected cases.

Immediate Assessment Required

First, determine symptom status within the past 6 months:

• Symptomatic: Any ipsilateral stroke, TIA, or amaurosis fugax
• Asymptomatic: No cerebrovascular symptoms referable to this lesion

Confirm stenosis severity using NASCET method (comparing minimal residual lumen to distal ICA diameter, not the bulb) 1. Duplex ultrasound is first-line, with CTA or MRA for confirmation 1.

For SYMPTOMATIC High-Grade Stenosis (≥70%)

CEA is strongly recommended and should be performed within 14 days of symptom onset, ideally after 48 hours of neurological stability 1. This timing is critical—the benefit diminishes significantly after 14 days.

Pre-intervention Management:

• Dual antiplatelet therapy (DAPT): Aspirin 81-325 mg + clopidogrel 75 mg for at least 21 days if not immediately revascularized 1
• Blood pressure control with antihypertensives 2, 3
• High-intensity statin therapy (target LDL <70 mg/dL) 1
• Document neurological examination within 24 hours before procedure 2, 3, 2

Revascularization Criteria:

• CEA is Class I recommendation for symptomatic 70-99% stenosis with documented 30-day stroke/death risk <6% 1
• Perform within 14 days, but wait at least 48 hours after acute stroke for neurological stability 1
• Do NOT revascularize if stenosis <50% (Class III recommendation) 1

Post-CEA Management:

• Long-term single antiplatelet therapy (aspirin or clopidogrel) 1
• Duplex ultrasound surveillance at 1 month, 6 months, then annually 2, 3, 2
• Yearly cardiovascular risk factor assessment 1

For ASYMPTOMATIC High-Grade Stenosis

Optimal medical therapy is the primary treatment; routine revascularization is NOT recommended in the absence of high-risk features and with life expectancy <5 years 1. This represents a major paradigm shift based on the most recent 2024 ESC guidelines and 2025 CREST-2/ECST-2 data 4.

Optimal Medical Therapy (OMT) - Universal for All Patients:

• High-intensity statin (target LDL <70 mg/dL, consider <55 mg/dL for very high risk) 1
• Single antiplatelet therapy: Clopidogrel 75 mg or aspirin 1
• Blood pressure control: Target <140/90 mmHg (or <130/80 mmHg if tolerated) 1
• Smoking cessation (mandatory)
• Diabetes control if present
• Lifestyle modification: Diet, exercise, weight management

Consider Revascularization ONLY If:

1. Age >75 years with 60-99% stenosis AND high-risk features (Class IIa) 1
2. Life expectancy >5 years 1
3. High-risk plaque features present (large lipid core, intraplaque hemorrhage, thin fibrous cap <165 μm, ulceration) 5, 6

High-risk features include:

• Contralateral carotid occlusion
• Silent cerebral infarcts on imaging
• Rapidly progressive stenosis
• Plaque vulnerability markers on advanced imaging

If Revascularization Considered:

• CEA preferred over carotid artery stenting (CAS) for average surgical risk patients >75 years (Class IIa) 1
• CAS may be considered for high surgical risk (hostile neck anatomy, prior neck radiation, contralateral vocal cord paralysis) (Class IIb) 1
• Perioperative stroke/death rate must be <3% to justify intervention 1

Critical Pitfalls to Avoid

1. Do NOT revascularize asymptomatic patients with <60% stenosis 1
2. Do NOT perform CEA in the first 48 hours after acute stroke (increased hemorrhagic transformation risk) 1
3. Do NOT delay CEA beyond 14 days in symptomatic patients (benefit diminishes) 1
4. Do NOT revascularize patients with severe disability (Modified Rankin Scale ≥3) that precludes functional recovery 2
5. Do NOT revascularize chronic total occlusions 2
6. Do NOT use ECST measurement method—always use NASCET 1

Special Considerations

If Concurrent Coronary Artery Disease Requiring CABG:

• Symptomatic carotid stenosis: Perform CEA before or simultaneous with CABG 7, 8
• Asymptomatic unilateral stenosis: Routine prophylactic CEA NOT recommended 7
• Bilateral high-grade or unilateral with contralateral occlusion: Consider staged CEA first 7

Carotid Artery Stenting (CAS) Specifics:

If CAS chosen (high surgical risk patients):

• DAPT (aspirin + clopidogrel) for minimum 30 days before and after 2, 3, 2
• Embolic protection device deployment recommended 2, 3, 2
• Consider transcarotid artery revascularization (TCAR) for reduced embolic risk 1, 9

Evidence Strength

The 2024 ESC guidelines 1 represent the most current and authoritative recommendations, superseding older 2011 guidelines 2, 3, 2, 10. The key paradigm shift is that modern intensive medical therapy has reduced annual stroke risk in asymptomatic patients to <1%, making routine revascularization no longer justified 11, 6, 4. The recent CREST-2 and ECST-2 trials (2025-2026) confirm that OMT alone is non-inferior to revascularization plus OMT in most asymptomatic patients 4.

For symptomatic stenosis ≥70%, CEA within 14 days remains the gold standard with Level A evidence 1, 10. The absolute risk reduction is 17% at 2 years (NNT = 6) 10, making this one of the most effective stroke prevention interventions available.